SPA
SRPT icon

Sherbrooke Park Advisers’s Sarepta Therapeutics SRPT Stock Holding History

Sherbrooke Park Advisers’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-14,914
Closed -$287K – 503
2025
Q3 		$287K Sell
14,914
-12,106
-45% -$216K 0.13% 285
2025
Q2 		$462K Buy
+27,020
New +$1.15M 0.2% 198
2024
Q1 		– Sell
-4,403
Closed -$425K – 989
2023
Q4 		$425K Buy
+4,403
New +$422K 0.2% 201
2023
Q3 		– Sell
-3,400
Closed -$389K – 612
2023
Q2 		$389K Buy
+3,400
New +$438K 0.2% 219

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Sherbrooke Park Advisers's SRPT Position: Q4 2025 in Review

Sherbrooke Park Advisers sold out of Sarepta Therapeutics (SRPT) in Q4 2025, closing a stake of 14,914 shares — an estimated $287K sold.

Sherbrooke Park Advisers first reported a position in SRPT in Q2 2023 and held it in 4 quarters. The position peaked at $462K in Q2 2025. 346 funds tracked by Wall St. Rank hold SRPT as of Q4 2025.

  • Sherbrooke Park Advisers reported no remaining Sarepta Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 14,914 Sarepta Therapeutics shares in Q4 2025, an estimated $287K.
  • Sherbrooke Park Advisers first reported a position in Sarepta Therapeutics in Q2 2023 and held it in 4 quarters.
  • Sherbrooke Park Advisers's Sarepta Therapeutics position peaked at $462K in Q2 2025.
  • 346 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.